Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, accounting for more than 18,000 cases each year within the United States. While roughly 60% of patients with DLBCL achieve durable remissions with existing chemotherapies, the prognosis of patients with refractory DLBCL is poor. The immune landscape of DLBCL is complex and further elucidation of the interplay between T cell activation and immunosuppression within the tumor microenvironment (TME) is necessary in order to better stratify patients and predict outcomes for therapy. This complexity, as well as the relevance of the spatial context of the various cell types within the TME necessitate the ability to simultaneously visualize biomarkers and phenotypic markers via multiplex immunohistochemical (mIHC) assays.

Jennifer Ziello, Shuling Zhang, Sarah Klein, Tyler Levy, Derek Papalegis, Lily Vu, Gabriella Spang, Arvin Ruiz and Giorgio Inghirami
Cell Signaling Technology, Inc., Danvers MA 01923